Obesity-related Inhibitors and Agonists
InquiryPrecision Targeting for Breakthrough Obesity Research
Protheragen delivers high-purity inhibitors and agonists, essential tools for global obesity research. These compounds, targeting key biological pathways involved in appetite, metabolism, and adipogenesis, accelerate and enhance the precision of obesity studies. By empowering researchers with these critical resources, Protheragen contributes directly to the advancement of effective obesity treatments.
Agonists activate receptors and mimic the action of natural substances in the body. Inhibitors block or reduce the activity of specific enzymes or receptors. Our product portfolio covers a wide range of obesity-related targets, including but not limited to:
- GLP-1 receptor agonists: They are used to study the role of GLP-1 in appetite regulation, blood sugar control, and energy metabolism.
- GIP receptor agonists: They are used to study the role of GIP in insulin secretion and fat metabolism.
- MC4 receptor agonists: They are used to study the role of the melanocortin system in appetite and energy homeostasis.
- Lipase inhibitors: They are used to study fat absorption and metabolism.
- Other related targets: We also provide inhibitors and agonists for other obesity-related targets, such as serotonin receptors.
Applications
- Prevention strategies: Obesity is a global health problem. Natural products are seen as potential avenues for exploring new, gentler ways of preventing obesity due to their wide range of sources, long history of use, and generally recognized safety profile.
- Development of multi-targeted therapeutics: Many natural products have favorable bioactivity and may act on obesity-related physiological processes through different mechanisms, such as appetite suppression, reduction of fat absorption, promotion of lipolysis, and improvement of metabolism. Co-treating natural products and investigating their therapeutic efficacy provides an effective strategy for exploring combinatorial anti-obesity therapies.
- Exploration of new molecular entities: Natural products are an important source for the discovery of novel anti-obesity drug molecules. By studying the active ingredients of natural products, scientists identify new molecules with potential anti-obesity activity and further develop and optimize them.
Advantages
- High purity and quality: High-purity activator and inhibitor products can reduce the interference of impurities on experimental results and ensure the accuracy and reliability of data.
- Strict quality control standards: High-quality research products are an important foundation for advancing the field of obesity research. During the production process, we carry out detailed tests on each batch of products, including purity tests, activity tests, etc., to ensure the consistency and stability of the products.
- Wide target coverage: We provide inhibitors and agonists for a wide range of obesity-related targets, including GLP-1 receptor, GIP receptor, MC4 receptor, lipase, etc., to meet the needs of researchers in different research directions.
- Supporting multiple research directions: Our products support multiple research directions, such as basic research, drug development, preclinical research, etc., and provide professional experimental guidance and technical consultation.
Publication
The incidence of obesity and type 2 diabetes mellitus is on the rise globally due to changes in human lifestyles and dietary structures. Anti-obesity drug development has become increasingly important. This paper introduces us to drugs and potential targets, such as activators and inhibitors, for the treatment of obesity and anti-diabetes. For example, GLP-1R can be used as an effective extrinsic appetite suppressant to regulate metabolism and has good applications in anti-obesity research. PPARγ activators can improve insulin sensitivity and glucose tolerance. SGLT2 inhibitors have some weight loss effects and increase energy expenditure, thus improving diet-induced metabolic changes.
Fig.1 Mechanisms of action of some drugs. (Pan, et al., 2023)
This article focuses on various receptor signaling pathways and summarizes the functions of some antidiabetic and anti-obesity drugs. These receptor signaling pathways may potentially be used to combat obesity and diabetes and drive the development of targeted novel therapeutic interventions. In addition to this, this study indirectly demonstrates the use of activators or inhibitors in obesity research.
Frequently Asked Questions
-
How are these products used in preclinical studies to facilitate the development of new drugs for obesity?
Preclinical studies include:
- Evaluating the efficacy and safety of these products using animal models
- Investigating mechanisms of action at the cellular and molecular levels
- Identification of novel anti-obesity biomarkers
- Other aspects
-
How to determine the optimal dose and route of administration of these activators and inhibitors in preclinical studies?
The optimal dose is determined by referring to published literature, product-related information, and conducting dose gradient experiments. The route of administration should be selected based on the experimental model and study objectives.
Protheragen is committed to providing obesity researchers with the highest quality products and the most professional services to help you make breakthroughs in the field of obesity research. Please feel free to contact us for quotes and ordering information for obesity-related activators and inhibitors.
Reference
- Pan, R.; et al. Treatment of obesity-related diabetes: Significance of thermogenic adipose tissue and targetable receptors. Frontiers in Pharmacology. 2023, 14: 1144918. (CC BY 4.0)
